These results strongly support our concept that the L1CAM is a potential therapeutic target in prostate cancer, and L1CAM-siRNA is a promising gene therapeutic approach for treating bone metastatic prostate cancers. This evidence concerns the gene L1CAM and prostate carcinoma.